J&J's Stelara Succeeds in Phase III Crohn's Disease TrialJ&J's Stelara Succeeds in Phase III Crohn's Disease Trial
Johnson & Johnson's Stelara (ustekinumab) was significantly better than placebo at inducing clinical response and remissions in patients with moderate to severe Crohn's disease, according to data from a late stage trial, providing ammunition for a potential expanded approval of the medicine. Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - October 20, 2015 Category: Allergy & Immunology Tags: Gastroenterology News Source Type: news
Johnson & Johnson's Stelara succeeds in Phase III Crohn's disease trial
(Reuters) - Johnson & Johnson's Stelara was significantly better than placebo at inducing clinical response and remissions in patients with moderate to severe Crohn's disease, according to data from a late stage trial, providing ammunition for a potential expanded approval of the medicine. (Source: Reuters: Health)
Source: Reuters: Health - October 19, 2015 Category: Consumer Health News Tags: healthNews Source Type: news
Novel Interleukin 17 Antibody Quickly Reduces PsoriasisNovel Interleukin 17 Antibody Quickly Reduces Psoriasis
Brodalumab cleared 100% of plaque in twice as many patients as ustekinumab, but the safety profile needs more study. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 2, 2015 Category: Consumer Health News Tags: Dermatology News Source Type: news
Brodalumab psoriasis results published, development plans continue
Brodalumab met all primary endpoints against its first-in-class rival, ustekinumab, and against placebo in two phase III trials of more than 3,700 patients with moderate to severe plaque psoriasis, investigators reported in the New England Journal of Medicine.
The results of the two studies, <a... (Source: Skin and Allergy News)
Source: Skin and Allergy News - September 30, 2015 Category: Dermatology Source Type: news
Improvements seen in adolescent psoriasis with ustekinumab
The CADMUS trial showed improvements in moderate to severe psoriasis in adolescent patients 12 years or older treated with ustekinumab, a study showed.
Treatment of psoriasis in pediatric patients is complicated by the limited number of approved treatments, despite approximately one-third of... (Source: Skin and Allergy News)
Source: Skin and Allergy News - September 30, 2015 Category: Dermatology Source Type: news
Ustekinumab Found to Be Effective in Adolescents With PsoriasisUstekinumab Found to Be Effective in Adolescents With Psoriasis
Adolescents with moderate to severe psoriasis may respond to the human monoclonal antibody ustekinumab as well as adults, with no unexpected side effects, a new study found. Reuters Health Information (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - September 1, 2015 Category: Dermatology Tags: Dermatology News Source Type: news
Secukinumab Beats Ustekinumab in Moderate to Severe PsoriasisSecukinumab Beats Ustekinumab in Moderate to Severe Psoriasis
Psoriasis patients experienced greater efficacy and improvement in health-related quality of life (HRQoL) on secukinumab than they did on ustekinumab in a new trial funded by Novartis. Reuters Health Information (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - June 30, 2015 Category: Dermatology Tags: Dermatology News Source Type: news
Lasting ustekinumab benefits seen in psoriatic arthritis
The final results of a 2-year, phase III study assessing the clinical efficacy and safety of ustekinumab in 615 patients with active psoriatic arthritis confirm that joint- and skin-related improvements are maintained.
Data from the randomized, double blind, placebo-controlled PSUMMIT 1 study...googletag.display('div-gpt-ad-cta'); (Source: Skin and Allergy News)
Source: Skin and Allergy News - June 22, 2015 Category: Dermatology Tags: CME-candidate RHEUM News RHEUM Psoriatic arthritis RHEUM Spondyloarthropathies SAN Clinical News SAN News SAN Psoriasis Source Type: news
Stelara Eases Spine Symptoms in PsA
(MedPage Today) -- Improvements with ustekinumab maintained for 2 years (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - June 16, 2015 Category: Dermatology Source Type: news
WCD: Ustekinumab succeeds as switch agent in psoriasis
VANCOUVER, B.C. – When adults with moderate to severe psoriasis fail one anti-TNF agent, most will still respond to another anti-TNF or ustekinumab, according to data from an investigation... (Source: Skin and Allergy News)
Source: Skin and Allergy News - June 11, 2015 Category: Dermatology Tags: RHEUM Conference News SAN Conference News RHEUM News RHEUM Spondyloarthropathies SAN Clinical News SAN News SAN Psoriasis RHEUM Psoriatic arthritis Source Type: news
IL-23 inhibitor topped ustekinumab against psoriasis
SAN FRANCISCO – An investigational interleukin-23 inhibitor for moderate to severe plaque psoriasis achieved almost twice the PASI 90 response rate of ustekinumab and generated no major safety signals, based on data from randomized trial of... (Source: Skin and Allergy News)
Source: Skin and Allergy News - April 2, 2015 Category: Dermatology Tags: CME-candidate RHEUM Conference News SAN Clinical News SAN News RHEUM News IMN News IMN Dermatology RHEUM Psoriatic arthritis Source Type: news
IL-17 Inhibitor Clears Psoriasis More Often
(MedPage Today) -- Brodalumab twice as likely to clear all lesions as ustekinumab. (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - March 23, 2015 Category: Dermatology Source Type: news
Secukinumab beat ustekinumab for psoriasis, with difference by week four
SAN FRANCISCO– Secukinumab met its primary endpoint in a head-to-head trial, achieving 21% more PASI 90 responses than ustekinumab in patients with moderate to severe plaque psoriasis, according to interim, week 16 results from the phase IIIb CLEAR trial.
Patients’ responses to the two biologic... (Source: Skin and Allergy News)
Source: Skin and Allergy News - March 21, 2015 Category: Dermatology Tags: SAN Clinical News SAN News SAN Psoriasis RHEUM News RHEUM Spondyloarthropathies RHEUM Psoriatic arthritis American Academy of Dermatology Source Type: news
Brodalumab achieved primary endpoints for moderate to severe psoriasis at 52 weeks
SAN FRANCISCO– Significantly more psoriasis patients who received the investigational biologic agent brodalumab achieved a PASI 100 response compared with those who received ustekinumab, and clinical responses persisted through 52 weeks, according to data from the pivotal phase III AMAGINE-2... (Source: Skin and Allergy News)
Source: Skin and Allergy News - March 21, 2015 Category: Dermatology Tags: SAN Clinical News SAN News SAN Psoriasis RHEUM Spondyloarthropathies RHEUM Psoriatic arthritis American Academy of Dermatology Source Type: news
Is This The Future Of Late-Stage Drug Development?
On Friday, Novartis announced that its anti-IL17A antibody secukinumab (Cosentyx™) demonstrated clear superiority over its rival, Stelara™ ustekinumab from Johnson & Johnson, an antibody against IL-12 and IL-23, in the treatment of psoriasis. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - December 15, 2014 Category: Pharmaceuticals Authors: David Grainger Source Type: news
